Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

Osteoporosis International

Volumn 23, Issue 3, 2012, Pages 1083-1090

  Roux, C ^a   Reid, D M ^b   Devogelaer, J P ^c   Saag, K ^d   Lau, C S ^e   Reginster, J Y ^f   Papanastasiou, P ^g   Bucci Rechtweg, C ^g   Su, G ^g   Sambrook, P N ^h  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone mineral density; Glucocorticoids; Osteoporosis; Risedronate; Zoledronic acid

Indexed keywords

25 HYDROXYVITAMIN D; PREDNISONE; RISEDRONIC ACID; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; GROUPS BY AGE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOPOROSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PREDNISONE; SEX FACTORS; VITAMIN D; YOUNG ADULT;

EID: 84857440380     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1800-1     Document Type: Article

References (31)

1. JP Devogelaer S Goemaere S Boonen JJ Body JM Kaufman JY Reginster S Rozenberg Y Boutsen 2006 Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club Osteoporos Int 17 8 19 16217586 1:CAS:528:DC%2BD2MXhtlWkt7rK 10.1007/s00198-005-2032-z (Pubitemid 41798023)
2. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update Arthritis Rheum 2001 44 1496 1503 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5 (Pubitemid 32642211)
3. L Caplan KG Saag 2009 Glucocorticoids and the risk of osteoporosis Expert Opin Drug Saf 8 33 47 19236216 1:CAS:528:DC%2BD1MXnsVWisg%3D%3D 10.1517/14740330802648194
4. PN Sambrook DR Hughes AE Nelson BG Robinson RS Mason 2003 Osteocyte viability with glucocorticoid treatment: relation to histomorphometry Ann Rheum Dis 62 1215 1217 14644862 1:STN:280:DC%2BD3srpsFGltA%3D%3D 10.1136/ard.2003. 008839 (Pubitemid 37500630)
5. S Benvenuti ML Brandi 2000 Corticosteroid-induced osteoporosis: pathogenesis and prevention Clin Exp Rheumatol 18 S64 S66 10948768 1:STN:280:DC%2BD3M%2FkvVGmtg%3D%3D
6. Roux C (2010) Osteoporosis in inflammatory joint diseases. Osteoporos Int. doi: 10.1007/s00198-010-1319-x
7. SL Silverman NE Lane 2009 Glucocorticoid-induced osteoporosis Curr Osteoporos Rep 7 23 26 19239826 10.1007/s11914-009-0005-4
8. PD Miller 2008 Anti-resorptives in the management of osteoporosis Best Pract Res Clin Endocrinol Metab 22 849 868 19028360 1:CAS:528:DC%2BD1cXhsVWmsbnK 10.1016/j.beem.2008.07.004
9. LI Plotkin SC Manolagas T Bellido 2006 Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs Bone 39 443 452 16627025 1:CAS:528:DC%2BD28XotFyksLg%3D 10.1016/j.bone.2006.02.060 (Pubitemid 44164640)
10. RG Russell NB Watts FH Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733 759 18214569 1:CAS:528: DC%2BD1cXltFyjurw%3D 10.1007/s00198-007-0540-8
11. KG Saag R Emkey TJ Schnitzer JP Brown F Hawkins S Goemaere G Thamsborg UA Liberman PD Delmas MP Malice M Czachur AG Daifotis Glucocorticoid-Induced Osteoporosis Intervention Study Group 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 292 299 9682041 1:CAS:528:DyaK1cXlsVOitr4%3D 10.1056/NEJM199807303390502 (Pubitemid 28366417)
12. DM Reid RA Hughes RF Laan NA Sacco-Gibson DH Wenderoth S Adami RA Eusebio JP Devogelaer European Corticosteroid-Induced Osteoporosis Treatment Study 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial J Bone Miner Res 15 1006 1013 10841169 1:CAS:528:DC%2BD3cXktFKhtbs%3D 10.1359/jbmr.2000.15.6.1006 (Pubitemid 30350063)
13. S Cohen RM Levy M Keller E Boling RD Emkey M Greenwald TM Zizic S Wallach KL Sewell BP Lukert DW Axelrod AA Chines 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309 2318 10555025 1:CAS:528:DyaK1MXnvVShsLs%3D 10.1002/1529-0131(199911)42: 11<2309::AID-ANR8>3.0.CO;2-K (Pubitemid 30333410)
14. C Roux P Oriente R Laan RA Hughes J Ittner S Goemaere O Di Munno JM Pouillès S Horlait B Cortet Ciblos Study Group 1998 Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss J Clin Endocrinol Metab 83 1128 1133 9543129 1:CAS:528:DyaK1cXitlynsLc%3D 10.1210/jc.83.4.1128 (Pubitemid 28496380)
15. JD Adachi KG Saag PD Delmas UA Liberman RD Emkey E Seeman NE Lane JM Kaufman PE Poubelle F Hawkins R Correa-Rotter CJ Menkes JA Rodriguez-Portales TJ Schnitzer JA Block J Wing HH McIlwain R Westhovens J Brown JA Melo-Gomes BL Gruber MJ Yanover MO Leite KG Siminoski MC Nevitt JT Sharp MP Malice T Dumortier M Czachur W Carofano A Daifotis 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial Arthritis Rheum 44 202 211 11212161 1:CAS:528:DC%2BD3MXht1yiu7o%3D 10.1002/1529-0131(200101)44: 1<202::AID-ANR27>3.0.CO;2-W (Pubitemid 32113136)
16. S Wallach S Cohen DM Reid RA Hughes DJ Hosking RF Laan SM Doherty M Maricic C Rosen J Brown I Barton AA Chines 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 277 285 11000340 1:CAS:528:DC%2BD3cXntlOlu74%3D 10.1007/s002230001146
17. JTT Iwamoto Y Sato 2007 Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis-usefulness of alendronate and risedronate Expert Opin Pharmacother 8 2743 2756 17956196 1:CAS:528: DC%2BD2sXht1Siu7fN 10.1517/14656566.8.16.2743 (Pubitemid 350193714)
18. S Boonen D Vanderschueren K Venken K Milisen M Delforge P Haentjens 2008 Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance J Intern Med 264 315 332 18823505 1:CAS:528:DC%2BD1cXht1Omt7%2FK 10.1111/j.1365-2796.2008.02010.x
19. J Compston 2010 Management of glucocorticoid-induced osteoporosis Nat Rev Rheumatol 6 82 88 20125175 1:CAS:528:DC%2BC3cXhsVSru7o%3D 10.1038/nrrheum.2009. 259
20. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 (Pubitemid 46698462)
21. KW Lyles CS Colón-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 (Pubitemid 350044800)
22. DM Reid JP Devogelaer K Saag C Roux CS Lau JY Reginster P Papanastasiou A Ferreira F Hartl T Fashola P Mesenbrink PN Sambrook 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 373 1253 1263 19362675 1:CAS:528:DC%2BD1MXktlyqtb4%3D 10.1016/S0140-6736(09)60250-6
23. SS Yeap DJ Hosking 2002 Management of corticosteroid-induced osteoporosis Rheumatology (Oxford) 41 1088 1094 1:CAS:528:DC%2BD38XovFOqtbY%3D 10.1093/rheumatology/41.10.1088 (Pubitemid 35203533)
24. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 1244564 1:STN:280:DyaE28%2FnsF2isw%3D%3D 10.1159/000180580
25. TP Van Staa RF Laan IP Barton S Cohen DM Reid C Cooper 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 3224 3229 14613287 10.1002/art.11283 (Pubitemid 37409336)
26. V Naganathan G Jones P Nash G Nicholson J Eisman PN Sambrook 2000 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use Arch Intern Med 160 2917 2922 11041898 1:STN:280:DC%2BD3crgt1Wlug%3D%3D 10.1001/archinte.160.19.2917 (Pubitemid 32009048)
27. SA Jamal VJ Swan JP Brown DA Hanley JC Prior A Papaioannou L Langsetmo RG Josse 2010 Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study Am J Kidney Dis 55 291 299 20042259 10.1053/j.ajkd.2009.10.049
28. M Tucci S Stucci S Strippoli F Silvestris 2010 Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus J Biomed Biotechnol 2010 457146 20671931 10.1155/2010/457146
29. PG Pecora B Kaplan 1996 Corticosteroids and ulcers: is there an association? Ann Pharmacother 30 870 872 8826575 1:STN:280:DyaK28vitl2ktw%3D%3D (Pubitemid 26243939)
30. LE Targownik LM Lix CJ Metge HJ Prior S Leung WD Leslie 2008 Use of proton pump inhibitors and risk of osteoporosis-related fractures CMAJ 179 319 326 18695179 10.1503/cmaj.071330
31. C Roux K Briot L Gossec S Kolta T Blenk D Felsenberg DM Reid R Eastell CC Glüer 2009 Increase in vertebral fracture risk in postmenopausal women using omeprazole Calcif Tissue Int 84 13 19 19023510 1:CAS:528: DC%2BD1MXitlegsg%3D%3D 10.1007/s00223-008-9188-4